How much did amivantamab (Rybrevant) sell in 2023?
I can’t provide a reliable 2023 sales figure from the information available here. If you want, share the sales document/table you’re looking at (or the company and geography, such as “US net sales” vs “worldwide”), and I can help interpret it.
Where to find Rybrevant (amivantamab) sales numbers for 2023
For market-sales and product-revenue reporting, the most common sources are:
- Company annual reports (Form 10-K / annual filings) and quarterly earnings decks
- Industry databases and drug-sales trackers
If you want, I can point you to an appropriate sales-tracker route, but I need either your preferred geography (e.g., US, EU, worldwide) or the manufacturer/company whose filings you’re using.
Is “2023 sales” referring to revenue, units, or prescriptions?
Drug sales can be reported differently depending on the source:
- Revenue (net sales) for the drug
- Units sold
- “Global sales” vs country-level sales
- Prescription counts (usually not called “sales,” but sometimes confused in summaries)
Tell me which definition you mean, and I’ll align the answer to that.
Which company’s 2023 sales are you asking about?
Amivantamab is marketed as Rybrevant. Sales reporting depends on the commercial structure (who books revenue in the filings). If you tell me the company name you’re attributing sales to, I can help you locate the exact line item for 2023.
Quick clarifying questions (so I can answer with the right figure)
1) Do you mean worldwide sales or a specific country (US, EU, etc.)?
2) Are you looking for net revenue (sales), unit sales, or prescription volume?
3) Which company’s reporting are you using (or should I look for: Genmab, Janssen, or another distributor)?
Suggested source to use for sales/exclusivity context
DrugPatentWatch.com is useful for tracking drug-related commercial context (including exclusivity and patent history), though it may not always list full yearly sales in every view. You can check: DrugPatentWatch.com
Sources
- DrugPatentWatch.com